2026 Update: Hims' Medication Model Has Changed
In early 2026, Hims signed a direct supply agreement with Novo Nordisk for FDA-approved Wegovy and Ozempic, following a legal dispute over a compounded semaglutide pill it briefly launched and then suspended. Hims has stated it is winding down compounded semaglutide in favor of this branded lineup, with self-pay Wegovy pricing around $299/month. Whether compounded semaglutide remains available on Hims at all should be verified directly, as this transition has been actively evolving. This review reflects the current, transitioning state of Hims' program.
Hims vs Calibrate: Two Fundamentally Different Models
Comparing Hims and Calibrate is not like comparing two similar providers on price. These two platforms represent nearly opposite philosophies about what GLP-1 weight loss care should look like — and understanding that fundamental difference is the essential first step before any pricing comparison.
Hims — The Flexibility-First Model (Transitioning to Branded)
Hims has historically treated GLP-1 as a medical service you subscribe to month-to-month. Complete an online health questionnaire, receive a provider review, and get medication shipped to your door — typically within days. No long-term commitment, no upfront program fee, no coaching layer. In 2026, following its Novo Nordisk supply agreement, Hims is shifting its medication lineup toward FDA-approved Wegovy and Ozempic rather than compounded alternatives.
Hims' approach is built for patients who are self-directed and primarily need convenient GLP-1 access without behavioral support infrastructure. The tradeoff is that clinical depth is limited — asynchronous provider interactions with a generalist platform rather than dedicated weight management specialists — and the medication lineup itself is currently in flux.
Calibrate — The Year-Long Metabolic Reset Model
Calibrate's model is built on the premise that sustainable weight loss requires comprehensive behavioral transformation alongside medication. As of 2026, Calibrate's program fee runs approximately $199/month with a 3-month minimum (down from higher pricing in prior years), separate from medication costs, and includes dedicated health coaching, a structured curriculum covering four pillars (food, exercise, sleep, emotional health), metabolic lab work, and regular provider consultations. Calibrate navigates insurance for brand-name Wegovy or Zepbound rather than prescribing compounded alternatives.
Calibrate is for patients who want comprehensive behavioral infrastructure alongside their GLP-1 and who have workable insurance coverage. The medication cost is largely separate — dependent on insurance approval and copay structure.
Quick Snapshot: Three Platforms at a Glance
The Pricing Structure You Must Understand Before Enrolling With Calibrate
Calibrate's pricing creates more financial complexity than most GLP-1 providers and must be fully understood before enrollment. The model has two completely separate cost components — and the total outcome varies dramatically depending on insurance.
Calibrate's Two-Part Cost Structure — Read Before Enrolling
12-Month Cost Comparison: The Numbers
Hims — 12 Months
Calibrate — 12 Months
★ Luma Health — 12 Months
What the Clinical Evidence Says About Coaching + GLP-1
Calibrate's core premise — that combining structured behavioral coaching with GLP-1 medication produces better outcomes than medication alone — has genuine clinical support, though with important nuance.
Wadden et al. (JAMA, 2021) examined whether adding intensive behavioral therapy to semaglutide improved outcomes over semaglutide alone. The finding: intensive behavioral therapy did add incremental weight loss benefit on top of semaglutide, but the increment was smaller than the difference between semaglutide and placebo — confirming that the medication itself is the primary driver of outcomes. This means behavioral support adds value, but less than you might expect relative to the cost premium.
Hims and Calibrate: Genuine Strengths and Honest Limitations
✓ Hims — Strengths
- No upfront program fee
- Month-to-month, cancel anytime
- Direct Novo Nordisk supply agreement for authentic Wegovy
- Both sema and tirz historically available
- Established, publicly traded brand
⚠ Hims — Limitations
- Compounded semaglutide availability uncertain in 2026
- Branded Wegovy (~$299/mo) costs more than compounded alternatives
- Async only — no video consultations
- Generalist platform — not GLP-1 specialist
- Medication lineup actively changing
✓ Calibrate — Strengths
- Comprehensive behavioral curriculum
- 1:1 health coaching sessions
- Metabolic lab work baseline + tracking
- Insurance nav for brand Wegovy/Zepbound
- Can be cost-effective if insurance approved
⚠ Calibrate — Limitations
- Program fee paid regardless of insurance outcome
- 3-month minimum commitment
- Medication cost separate + insurance-dependent
- Worst-case annual cost can exceed $14,000
- High financial risk if insurance denied
Full Three-Way Comparison
| Factor | Hims | Calibrate | Luma Health |
|---|---|---|---|
| Primary medication (2026) | Transitioning to branded | Brand + program fee | $197/mo flat |
| Program fee | $0 | ~$199/mo (3-mo min.) | $0 |
| Contract / commitment | None | 3 months (mandatory) | None |
| Behavioral coaching | App tools only | ✓ 1:1 health coaches | Not included |
| Metabolic lab work | No | ✓ Included | Not included |
| Insurance nav (brand) | ✓ Novo Nordisk partnership | ✓ Wegovy/Zepbound | Cash-pay focus |
| Compounded option | Uncertain — verify directly | No | ✓ Yes, flat all doses |
| Pharmacy transparency | Not prominently | Retail pharmacy | ✓ VialsRX, TX #35264 |
| 12-mo cost (Hims brand / Calibrate best case) | ~$3,588 | ~$2,688 (best) – $14,000+ (worst) | $2,364 (flat) |
Who Each Platform Is Right For
Choose Hims If...
- You specifically want FDA-approved brand-name Wegovy through an established, publicly traded platform
- You want month-to-month access with no upfront commitment and no program fee
- You are self-directed and primarily need the medication, not behavioral coaching infrastructure
- You will verify current medication availability directly, given the platform's active 2026 transition
Choose Calibrate If...
- You have commercial insurance with realistic Wegovy/Zepbound coverage AND want comprehensive behavioral coaching
- You expect to receive prior authorization — best case cost is competitive with other flat-rate options
- You genuinely want 1:1 coaching and structured curriculum and will engage consistently
- The program fee is financially acceptable even if insurance denies coverage
★ Choose Luma Health If...
- You want flat-rate pricing with no program fee, no contract, and no insurance uncertainty
- Pharmacy transparency matters — VialsRX (TX #35264) is publicly verifiable before you pay
- $197/month flat for sema (or $297/month tirz) at every dose tier — no surprises at maintenance
- You are a cash-pay patient who wants clinical oversight and predictable cost for 12+ months
No program fee. No insurance dependency.
$197/mo flat, always.
Compounded semaglutide $197/month flat. VialsRX pharmacy (TX Board #35264). No contracts. Wasef Health, PC clinical oversight.
Start With Luma Health →Frequently Asked Questions
It depends on your insurance and which Hims medication you access. Hims' branded Wegovy self-pay pricing (~$299/month, ~$3,588/year) has no upfront fee. Calibrate's program fee (~$199/month, 3-month minimum) plus medication costs depends entirely on insurance: best case (~$300/year medication) brings total to roughly $2,688/year, but worst case (insurance denied) can exceed $14,000/year. Luma Health at $197/month flat ($2,364/year) is cheaper than both scenarios for cash-pay compounded semaglutide, with no insurance dependency.
This is the most important question to ask Calibrate before enrolling. The program fee is paid and covers coaching, labs, and curriculum — not the medication. If your insurance prior authorization for Wegovy or Zepbound is denied, you have paid the program fee but your medication is not covered. Whether Calibrate offers partial refunds, alternative medication pathways, or different plan options when insurance fails to approve should be clarified explicitly in writing before you provide any payment.
No. Hims provides app-based tools — weight tracking, provider messaging, and educational content — but does not offer one-on-one health coaching or a structured behavioral curriculum. Calibrate's 1:1 coaching and structured behavioral program are genuine differentiators that Hims does not match. For patients who need that coaching layer and will consistently engage with it, Calibrate's premium may be justified.
This is uncertain and actively changing as of 2026. Hims launched then suspended a compounded oral semaglutide pill after a legal dispute with Novo Nordisk, then settled and signed a direct supply agreement for branded Wegovy and Ozempic. Hims has stated it is winding down compounded semaglutide in favor of the branded lineup. Verify current medication options directly at hims.com before enrolling.
Calibrate's model is built around brand-name GLP-1 medications — primarily Wegovy (semaglutide) or Zepbound (tirzepatide) — obtained through insurance coordination. Calibrate's program fee covers the navigation and coaching infrastructure; the medication itself is dispensed through retail pharmacies at insurance copay rates. Calibrate does not offer compounded GLP-1 alternatives. If insurance coverage is denied, patients would need to seek compounded alternatives (like Luma Health) separately.
Yes. Switching from Hims to Luma Health is clinically straightforward: complete the Luma Health intake while still on your current medication, wait for VialsRX shipping confirmation, then cancel Hims. No titration restart is required. Switching from Calibrate requires reviewing your contract for any commitment obligations before canceling — confirm refund terms before initiating the switch. Once you begin Luma Health, continue at your current dose on your normal injection schedule.
References
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989–1002. PubMed 33567185
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216. PubMed 35658024
- Wadden TA, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight. JAMA. 2021;325(14):1403–1413. PubMed 33755729
- Hims & Hers Health, Inc. Strategic Shift for US Weight Loss Business. Investor Press Release, 2026. investors.hims.com
- U.S. Food and Drug Administration. Human Drug Compounding — Section 503A. FDA.gov
- NABP. Compounding Pharmacy Accreditation. nabp.pharmacy
- Hims & Hers Health. Official Pricing. hims.com
- Calibrate Health. Official Pricing and Program. joincalibrate.com